Back to Directory Shawn Chiambah Email shawn.chiambah@nih.gov Institution Pharmaceutical Affairs Branch, Division of AIDS Address Division of AIDS/OCSO/NIAID/NIH 5601 Fishers Lane Bethesda, MD 20892-3593 USA Request an Update Affiliated Studies IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Therapeutics Study Status In Development
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending
IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Therapeutics Study Status In Development